In the first of the two Cancer Research articles describing these and related compounds, it was proposed that the vitaletheine modulators may require activation to the sulfenic acid, either by oxidation or through rearrangement of a benzyl derivative. Recent evidence in the treatment of cancer seems to support this hypothesis. Although neither regimen has been optimized, the benzyl derivative appears to be more effective than vitalethine in treating melanoma, especially when dead tumor cells are also administered to mice bearing uniformly fatal melanoma.
Structural similarities with a variety of other compounds known to stimulate the immune system (or to have anti-tumor, anti-autoimmune, and anti-histamine activity) predict applications for the vitaletheine modulators in a variety of problematic diseases. Among the Patents that have issued on the use of vitaletheine modulators in cell culture and for the treatment of cancer, the US Patent is the best source for additional chemical information about these compounds. Additional chemical information and tips on synthesis are provided in this Web Site and will be updated as information becomes available.
||WWW Links||Outline||e-mail us|